Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared posts on X:
“I’ve looked at this EHA2026 slide 100 times, but it still always makes me pause.
Unexpected early relapses so scary for patients with myeloma, and historically post-PD OS in FHRMM ≤ 2 years no matter what we do.
Here, off-the-shelf Tx boosted 3-yr PFS from 0% to 77%. Giving these patients a fighting chance for deep and durable remissions.”
Other articles featuring Rahul Banerjee on OncoDaily.